Verastem (VSTM) Expected to Announce Earnings on Thursday

Verastem (NASDAQ:VSTM) is expected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Verastem to post earnings of ($0.76) per share and revenue of $0.15 million for the quarter.

Verastem Stock Performance

NASDAQ VSTM opened at $7.15 on Wednesday. The stock has a market capitalization of $318.23 million, a price-to-earnings ratio of -2.24 and a beta of 0.60. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The business’s 50 day moving average is $5.88 and its two-hundred day moving average is $4.39. Verastem has a 12-month low of $2.10 and a 12-month high of $13.52.

Wall Street Analysts Forecast Growth

VSTM has been the topic of a number of research reports. Guggenheim restated a “buy” rating on shares of Verastem in a report on Friday, January 24th. Mizuho increased their price target on Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. StockNews.com lowered Verastem from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Verastem in a research note on Thursday, December 19th. Finally, Royal Bank of Canada lifted their target price on Verastem from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.63.

Insider Transactions at Verastem

In related news, CEO Dan Paterson sold 8,568 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total value of $44,896.32. Following the completion of the sale, the chief executive officer now directly owns 347,581 shares of the company’s stock, valued at $1,821,324.44. The trade was a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders have sold 10,367 shares of company stock valued at $53,990. 2.20% of the stock is currently owned by insiders.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.